Identification of Potential Biomarkers in Papillary Thyroid Carcinoma Based on Proteomics
Yu Sun,Jiaxuan Sun,Xiaona Gao,Tiefeng Shi,Maoqing Wang
DOI: https://doi.org/10.2147/ott.s465636
IF: 4
2024-11-04
OncoTargets and Therapy
Abstract:Yu Sun, 1, &ast Jiaxuan Sun, 1, &ast Xiaona Gao, 1 Tiefeng Shi, 1 Maoqing Wang 2 1 Department of Thyroid Surgery, The Second Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China; 2 Department of Nutrition and Food Hygiene, School of Public Health, Harbin Medical University, Harbin, People's Republic of China &astThese authors contributed equally to this work Correspondence: Tiefeng Shi, Department of Thyroid Surgery, The Second Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China, Email Maoqing Wang, Department of Nutrition and Food Hygiene, School of Public Health, Harbin Medical University, Harbin, People's Republic of China, Tel +86-451-87502876, Fax +86-451-87502885, Email Background: To identify biomarkers of papillary thyroid carcinoma (PTC) and explore the possible pathogenic mechanism. Methods: This study included five patients with PTC. Protein expression of cancer tissues and adjacent normal thyroid tissues from each patient were analyzed by TMT proteomics technology. Differentially expressed proteins were identified, and functional annotation of differentially expressed proteins was performed by bioinformatics and pathway enrichment analysis. Results: A total of 639 differentially expressed proteins were identified, including 278 upregulated and 361 downregulated proteins. Six upregulated proteins were identified as potential specific markers of PTC. Conclusion: Differentially expressed proteins may represent new molecular markers of PTC. These differentially expressed proteins and the related pathways may provide new insights into the pathogenic mechanisms of PTC. Keywords: papillary thyroid carcinoma, TMT, proteomics, PRM, molecular markers Thyroid cancer is a relatively common endocrine system disease that tends to affect younger individuals, and its incidence is gradually increasing worldwide, including in China. 1–4 The most common pathological type of thyroid cancer is papillary thyroid carcinoma (PTC), accounting for about 85% of all thyroid cancers. 5 The 2015 American Thyroid Association guidelines currently recommend active surveillance for patients with low-risk papillary thyroid carcinoma. Ultrasound-guided ablation has also been used to treat low-risk papillary thyroid carcinoma and achieved good results. 6–8 However, some PTCs are highly invasive, and local and distant metastases can occur in the early stage. If not treated in time, PTC can seriously affect patient prognosis and even endanger life. The current diagnostic methods for papillary thyroid carcinoma are not sufficiently accurate. Furthermore, symptoms at the early stage are not obvious, and most patients have already reached the advanced stage at diagnosis, which leads to poor prognosis. Therefore, identifying a new method for early diagnosis and prognosis evaluation of PTC is critical. While the accuracy of lymph node diagnosis with ultrasound is high, the diagnostic sensitivity for central compartment lymph node metastasis (CLNM) is only 10.9% to 36.2%. 9 Some surgeons still treat patients by surgical resection. Central compartment lymph node dissection (CLND) reduces the tumor recurrence rate and improves the TNM staging of some patients. 10 Preventive CLND increases the risk of surgical complications including recurrent laryngeal nerve injury, parathyroid injury and other surgical complications. 11 In this study, we used proteomics to search for potential specific and sensitive biomarkers for PTC, which can aid in the improvement of the early diagnosis rate of PTC. The analysis of differential protein metabolic pathways in PTC may also provide new insights into the pathogenesis of PTC. This study was approved by the ethics committee of The Second Affiliated Hospital of Harbin Medical University and all patients have agreed with and signed on the consent form before. Thyroid cancer tissue and adjacent normal tissue samples were collected from patients undergoing surgical resection in the Department of Thyroid Surgery, The Second Affiliated Hospital of Harbin Medical University from January 2020 to January 2021. Inclusion criteria were as follows: (1) subtotal or total thyroidectomy was performed in the thyroid surgery department of the Second Affiliated Hospital of Harbin Medical University, and lymph node dissection in the central region of the neck (region VI and region VIII) was performed during the operation; (2) postoperative pathology confirmed as single-focal PTC; and (3) ultrasound examination of the thyroid in the Second Affiliated Hospital of Harbin Medical University within 2 months before oper -Abstract Truncated-
oncology,biotechnology & applied microbiology